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ABSTRACT
Introduction: Bone morphogenetic protein (BMP)-2 is a potent stimulator ofnew bone
formation with a potential role in dental regenerative therapies and improving dental
implants. There are studies showing that effects ofBMP-2 on bone formation may be
mediated in part by prostaglandins (PGs) [1] or enhanced by exogenous addition of
PGs (Sasaoka, et al, BBRC 2004; Inoue et al, Bone 1996). Since prostaglandin E2
(PGE2) is a potent stimulator of osteoclast (OC) formation and since BMP-2 at high
doses can induce cyclooxygenase-2 (COX-2) expression and PGE2 production, we
examined the effects ofBMP-2 alone and in combination with PGE2 on osteoclast
formation in vitro.
Materials and Methods: Bone marrow (BM) was flushed from C57B1/6 mouse tibia,
plated in 48, 12 and 6 well plates at 1X106 cells/cm2, and cultured for 6-10 d.
Treatment groups (n=3 wells) were control (vehicle), PGE2 (1 gM), BMP-2 (100
ng/ml), and PGE2 + BMP-2. Osteoclasts, defined as multinucleated cells (MNCs) (>3
nuclei/cell) that stained positive for tartrate resistant acid phosphase (TRAP), were
counted, mRNA levels for receptor activator ofNFb ligand (RANKL), which is
necessary for osteoclast differentiation, and for osteoprotegrin (OPG), the decoy
receptor for RANKL that inhibits osteoclast formation, were measured by quantitative
(q) PCR.
Results: In 12-well plates, no OCs formed in control cultures and only a few in BMP-
2 treated groups (range 0-2). PGE2 and PGE2+BMP-2 both caused similar significant
increases (p<0.05) in OC counts on days 7 (24.3+7.4 and 14.7+/- 11.7) and 8 (42.0+5.3
and 48.7+4.5), respectively. On day 9, however, the combination ofPGE2+BMP-2
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(76.3+20.5) showed a significant synergistic increase in number of OC cells compared
to PGE2 (21.3+/-3.3) alone. There was a significant increase in RANKL mRNA on day
7 (2-fold) and a significant decrease in OPG mRNA on days 7 (50%), 8 (75%) and 9
(90%) in the PGE2+BMP-2 group compared to the PGE2 treatment group. The ratio
ofRANKL to OPG mRNA was significantly higher by 4-times and 43-times on days
7 and 8, respectively, for the combination group. Similar results were observed in 6-
well and 48-well BM cell cultures.
Conclusion: We conclude that BMP-2 alone did not increase OC, but did increase OC
formation in the presence of exogenous PGE2. The effect of the BMP-2+PGE2
combination correlated with an increase in RANKL and a decrease in OPG
expression. It is possible that the increased activation of resorption in vivo by PGE2
will permit BMP-2 to have a greater anabolic effect by increasing the number of
remodeling sites at which BMP-2 can act.
Review of the Literature
INTRODUCTION
Bone morphogeneticprotein (BMP)
BMP was originally named by Urist in 1965 and consisted of adult bone
extract capable of inducing new endochondral bone formation at ectopic sites in
rodents [2]. Currently, many genes responsible for bone induction have been cloned
and a greater understanding oftheir roles and signaling pathways are becoming
apparent (Figure 1) [3].
BMPs are members of the transforming growth factor-C/(TGF-/3) superfamily
(Figure 2) [4] and perform a wide range ofbiological functions in various cell types
[3]. The BMP subfamily contains a pattern of seven conserved cysteine residues in the
carboxy-terminal and this is the location in which the activity resides [3]. BMPs bind
to Type I and Type II transmembrane serine/thronine kinase receptors with different
affinities. The BMP subfamily is divided into subgroups composed of structurally and
functionally similar molecules (Figure 2) [4, 5]. The subgroups are the BMP2/4
group, osteogenic protein-1 (OP-1) group and growth/differentiation factor-5 (GDF-5)
group or cartilage-derived morphogenetic protein- 1 (CDMP- 1) group. Most members
ofthe BMP-2/4 group and OP-1 have been shown to induce cartilage and bone
formation, whereas the GDF-5 group can induce cartilage and tendon-like tissues [3].
This has been shown through recombinant BMPs being ectopically implanted in rats
[6]. BMPs also can initiate endochondral bone formation [7].
Secreted BMP also binds extracellular antagonists. For example, noggin binds
BMP-2, -4, -7, and GDF5 and 6; chordin binds BMP-2, -4, -7; folistatin binds BMP-2,
-4, -7 and -11/BDF11; gremlin binds BMP-2, -4 and GDF5 [8, 9].
BMPs are important mediators in skeletal development, differentiation,
maturation and homeostasis. In skeletal development, BMPs have been localized to
sites and times associated with mesenchymal condensation and cartilage
differentiation [3]. Hence, these are important molecules in limb development and are
thought to interact with fibroblast growth factors (FGFs) and sonic hedgehog (Shh)
[10]. BMP-2 and-4 transcripts are found in the limb apical ectodermal ridge (AER)
and zone ofpolarizing activity (ZPA) [11]. BMP-2 and -4 knockout mice die early in
embryogenesis [12]. BMP-7 knockout mice survive until birth and only have mild
limb and skeletal anomalies [13]. The GDF5 null mouse phenotype demonstrates
brachypodism (shortening of long bones, decreased number of digits and misshapen
paw bones) [14]. The model resembles the mutation in the human GDF5 gene [15].
BMP-6 null mice appear to have normal skeletons at birth [16] suggesting no
involvement in skeletal development (or compensation by other BMP genes), however
BMP-6 is present in chondrocytes undergoing hypertrophy and replacement by bone
[17]. BMP-5 lacking mice show a phenotype associated with short ears and affected
cartilaginous structures ofthe ribs and sternum 18]. The most abundant BMP in the
body is BMP-3. However, loss ofBMP-3 does not show any effect on embryogenesis
in relation to the skeleton 19]. Adult BMP-3 null mice have twice the trabecular
volume ofwild-type littermates and therefore an increased bone density. It is thought
that BMP-3 interferes with BMP-2 activation of transcriptional events through the
activin receptor pathway [3].
BMPs potentially have several therapeutic applications" 1. stimulation ofbone
formation in orthopedic procedures, such as fracture healing; 2. stimulation ofnew
bone formation to support dental implants; and 3. enhancement of fixation of
prosthetic metal implants (osseointegration). Small amounts ofBMPs, delivered with
a matrix or carrier to prolong a slow release, have been shown to increase bone
formation drastically [3]. The application ofBMPs in orthopedic surgery have been
utilized in models where defects are of a critical size (i.e. unable to heal
spontaneously). For example, rhBMPs and BMP-7/OP-1 have been shown to heal
large defects in many species [3]. BMPs also have potential dental and craniofacial
applications. In particular, BMP therapy has been proposed for bone augmentation
associated with extraction sockets, bone loss associated with periodontal disease,
dental implant osteointegration and in sinus lifts. In spinal fusion procedures, BMPs
have been substituted for bone grafts and tested successfully in animal models as well
[3]. In bone fracture repair, BMPs are likely mediators and provide an attractive site
for therapeutic intervention. They have been shown to accelerate fracture repair in
animal models by increasing the amount and maturation of the callus [3]. BMPs
potentially could be combined with hydroxyapatite ceramics to substitute for bone
grafts [20]. Despite the many potential clinical applications ofBMPs, the downside is
that milligrams ofprotein are required to elicit new bone formation. The lower
responsiveness ofhumans to BMPs creates a high cost for treatment and to improve
the cost-effectiveness of this protein treatment, the use of additional drugs, such as
PGE2,to enhance BMP action is being investigated [21 ].
Not only do BMPs play an important role in skeletal development,
differentiation and maturation, they are also involved in the remodeling of the adult
skeleton, which involves both osteoblasts (OBs) and osteoclasts (OCs) derived from
the bone marrow. BMPs are thought to provide a signal for bone marrow stem cells to
differentiate into osteoblasts [3]. BMPs are present in bone and OBs have been shown
to secrete BMPs both in vivo and in vitro [22]. In remodeling, BMPs may link bone
formation and bone resorption by regulating specific osteoblast transcription factors
associated with RANK, RANKL and OPG [23, 24]
Little is known about the effects ofBMPs on OCs and bone resorption.
Previous results from our lab have shown that in cultured bone marrow cells from
mice with disruption ofboth alleles of COX-2 (COX-2-/- mice) and mice with normal
COX-2 (COX-2+/+ mice), BMP-2 induced osteoclast formation in cells from COX-2
+/+ mice, but not in cells from COX-2 -/- mice [1 ]. The addition ofPGE2 (1 gM)
stimulated an increase in OCs in both COX-2+/+ and -/- mice. The addition ofboth
BMP-2 and PGE2 to the cultures showed a synergistic increase in OC number. This
suggests that BMP-2 may play a role in bone resorption and that PGE2 produced by
COX-2 may enhance this role. It is possible, then, that the presence of inflammation
or other situations in which COX-2 is induced, such as mechanical loading, fracture
healing, or tooth movement, may enhance the resorptive effects ofBMP-2. In the
same study by Chikazu et al. [1 ], it was shown that some of the anabolic effects of
BMP-2 on calvarial osteoblastic cells in culture also depended on the BMP-2
stimulated expression of COX-2 and PGE2 production. Hence, it would be useful to
know more about the interaction ofBMP-2 and PGE2 on osteoclast formation to help
us understand whether PGE2 will predominantly enhance the anabolic or the catabolic
effects ofBMP-2 and ifwe can inhibit the catabolic interaction ofBMP-2 and PGE2
without diminishing the anabolic interactions.
Prostaglandin E_ (PGE
Upon physiological or inflammatory stimulus, membrane phospolipids (PL)
are first metabolized to arachidonic acid (AA), and then follow one of three paths
(Figure 3)" 1. the cyclooxygenase (COX) path to prostanoids (prostaglandins-PGs and
thromboxanes-THXs), 2. the lipoxygenase path (leukotrienes, lipoxins, hydroxy-fatty
acids) and 3. the cytochrome P-450-dependent epoxygenase path (epoxy and omega
derivatives) [25]. These 20-carbon poly-unsaturated fatty acid (FA) derivatives are
termed eicosanoids and function as local hormones.
PG production follows the COX pathway. AA is converted to PGE2 by the
enzyme COX and then hydroxylated to PGH2. Diffusible PGH2 is then converted by
tissue-specific isomerases and reductases to PGE2, PGD2, PGF2, PGI2 (prostacyclin)
and THX. COX (formerly known as PG endoperoxide H synthase or PG G/H
synthase (PGHS)) has two isoforms, COX-1 and COX-2, encoded by separate genes
[26]. COX-1 is encoded by a 22 kb gene with 11 exons and is expressed constitutively
[27]. COX-2 is encoded by a 8 kb gene with 10 exons and is inducible [26]. Even
though COX-1 and -2 are similar in their enzymatic mechanisms, their functional roles
differ. COX-1 produces PGs responsible for the "housekeeping" functions such as the
maintenance of renal blood flow, platelet aggregation and gastric cytoprotection.
COX-2 produces PGs involved with inflammation and pain [25].
COX is irreversibly inactivated when acetylated by non-steroidal anti-
inflammatory drugs (NSAIDs) like acetylsalicylic acid (Aspirin). Drugs like
ibuprofen reversibly inhibit COX. Next generation drugs like rofecoxib (Vioxx) and
celecoxib (Celebrex) are specific COX-2 inhibitors which decrease the side effect of
the general COX inhibitors on housekeeping functions [28]. Glucocoriticoids also
have an inhibitory effect on PG production by decreasing COX-2 mRNA and protein
formation [29]. Estradiol has also been shown to decrease PG production in culture,
however the mechanism is not through down regulation of COX-1 or -2 [30].
PGE2 acts through G-protein-coupled surface receptor subtypes EP 1-4, which
are expressed differently depending on the tissue type [21]. The EP4 receptor is the
only one ofthe four receptor subtypes that mediates the PGE2-induced anabolic action
in bone formation in rodents [31-34]. Additional studies have suggested that an EP2-
selective agonist may be able to enhance bone healing in dogs or rats [35, 36]. The
EP2 and 4 receptors have been implicated in the stimulation ofRANKL production in
the process of osteoclastogenesis in the presence of OB/stromal cells [37, 38]
PGs also play a major role in bone metabolism and can stimulate both bone
formation and bone resorption [39-41]. Specifically, PGs of the E series are the most
potent activators ofbone resorption [42]. In marrow cultures, PGE2 stimulates
osteoclast (OC) formation [43] and may mediate some ofthe actions of agonists like
IL-1 [44-46], TNF-ot [45], PTH [47], Vitamin D (1,25 (OH)2 D3) [48], IL-11 [49],
IL-6 [50], IL-17 [51 ], phorbol ester [52] and FGF-2 [53]. More important than PGs in
OC maturation is the direct interaction between receptor activator ofNF-B ligand
(RANKL) and RANK on the OBs and OCs, respectively [54]. RANKL is also known
as TNF-related activation-induced cytokine (TRANCE) [55, 56] and osteoclast
differentiating factor (ODF) [57]. Also important in this mechanism is osteoprotegrin
(OPG), which acts as soluble competitive inhibitor and binds to RANKL (also known
as OPGL), thus blocking binding and activation ofRANK on the OC surface [57].
OPG knockout mice show decreased bone density [58], defects in tooth eruption and
osteoclastogenesis [59], while mice with over expression of OPG show increased bone
density [60]. It is thought that PGE2 released by OBs has an auto-amplification effect
which further stimulates OBs to increase COX-2 and RANKL expression [4]. Using
co-culture methods, it has been shown that periodontial ligament (PDL) cells also
require cell-to-cell contact for osteoclastogenesis [61]. RANKL has also been shown
in OBs, osteocytes and fibroblasts during the application of orthodontic forces [62].
The RANKL/OPG ratio has even been implicated in root resorption associated with
heavy orthodontic forces applied in rats [63].
Osteoclast Cultures
Osteoclasts are multinucleated cells derived from hematopoietic stem cells and
are responsible for bone resorption. In vitro, multinucleated osteoclast-like cells
(MNC) can be cultured from bone marrow stromal cells in the presence of certain
mediators which primarily target OBs [64]. Spleen cultures contain precursor OCs,
but no OBs. Therefore, this culture requires supplementation with M-CSF and soluble
RANKL. It has been shown that PGE2 can increase the combined effects ofRANKL
and M-CSF to stimulate OC formation [65]. Our lab found that in this system, there
was a 50% reduction in osteoclasts when the cells came from COX -/- mice due to the
increased expression of GM-CSF, an inhibitor of OC formation in these cultures [66].
Bone marrow cultures on the other hand contain both pre-osteoblasts and pre-
osteoclasts and therefore do not require supplementation with either RANKL or M-
CSF. Co-cultures combining osteoblasts from the calvarium and pre-osteoclasts from
spleen or OC precursor cells from bone marrow and OBs from calvarium are also
used. One cell line ofOC precursors (e.g. RAW264.7) is available.
In spleen cultures, PGE2 decreased the number of OCs formed in the presence
ofRANKL and M-CSF at 5-6 days of culture and increased OCs at 8-9 days compared
with cultures without PGE2 [67]. Also, PGEz decreased OC apoptosis at day 7 and
increased pit formation at day 8 [67]. It was concluded that PGE2 has a initial
inhibitory effect on OC formation in spleen cell cultures and a later stimulatory effect
mediated by the EP2 receptor [67]. A previous study reported that the stimulatory
PGE2 effect in spleen cell cultures disappeared in EP2 receptor knock-out mice, but an
EP4 receptor antagonist did not have any effect on blocking the stimulation [66]
BMP-2 has been shown to induce COX-2 expression in cultured OB [68].
PGs can stimulate bone formation or resorption and thus may mediate some effects of
BMP-2. In vitro, a very high dose ofBMP-2 induced OC formation in cells from
COX-2 +/+, but not COX-2 -/- mice 1 ]. Furthermore, the addition ofboth PGE2 and
BMP-2 showed a synergistic effect on OC number in vitro when compared to PGE2
and BMP-2 alone 1].
RATIONALE
Considering the significant potential ofBMPs for therapeutic intervention to
improve fracture healing, implants and bone remodeling, it would be very useful ifwe
understood how BMPs interact with other agents that can enhance their effects on
bone.
HYPOTHESIS
Previous results [1] have shown the stimulatory effects ofBMP-2 at high doses
on osteoclastogensis in the presence of endogenous prostaglandins. We hypothesize
that exogenous PGs will enhance BMP-2 stimulation of OC formation. Our goals are
to show that the combination ofBMP-2+PGE2 produces more OCs than PGE2 alone
and that the increased effect of the is the result of increased RANKL and decreased
OPG expression.
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OBJECTIVES
The purpose of this research is to determine the role ofBMP-2 and PGE2 on
osteoclastogenesis in both bone marrow and spleen cell cultures.
OBJECTIVE OF RESEARCH
Bone morphogenetic protein (BMP)-2 is a potent stimulator ofbone formation.
The therapeutic application ofmaking new bone with BMP-2 is currently being
studied in osteoporosis, fracture healing, and dental implants. However, BMP-2 has
also been shown to stimulate the formation ofbone-resorbing cells, osteoclasts. BMP-
2 has been shown by our laboratory to increase the formation of osteoclasts in bone
marrow cultured for 7 days [1]. The ability ofBMP-2 to increase osteoclasts was
dependent on the BMP-2 induction of cyclooxygenase (COX)-2. Furthermore, the
addition of one of the products of the COX-2 pathway, prostaglandin E2 (PGE2), to
BMP-2 treated cultures synergistically increased the formation of osteoclasts. The
goal of the present study is to examine the BMP-2 regulation of osteoclast formation
in more depth and to determine the mechanism by which PGE2 exerts its synergistic
effects.
Osteoclastogenesis is dependent on the expression of the receptor activator of
nuclear factor (NF)-:B ligand (RANKL) by osteoblasts, the bone-forming cells. The
receptor for RANKL, RANK, is expressed on osteoclastic precursors. Osteoblasts
also produce a soluble receptor for RANKL, which does not activate the RANK
signaling pathways, called osteoprotegrin (OPG) and is an inhibitor of
osteoclastogenesis. Marrow cultures contain both osteoblast and osteoclast precursors
and therefore can be used to compare the BMP-2 regulation ofRANKL and OPG
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expression with osteoclast formation. Spleen cultures contain only osteoclast
precursors, not osteoblasts, so they must be supplied with exogenous RANKL to make
osteoclasts. Spleen cultures can be used to study effects ofBMP-2 on osteoclast
precursors. Our goal is to determine if the effects ofBMP-2 and BMP-2+PGE2 are
mediated via effects on osteoblasts to regulate expression ofRANKL or OPG or via
effects on osteoclastic precursors.
The specific aims are (1) to examine BMP-2 +/- PGE2 stimulated osteoclast
formation in spleen cultures treated with RANKL and M-CSF; (2) to determine the
effects ofBMP-2 +/- PGE2 on osteoclast formation in marrow culture by performing a
time course; and (3) to examine the effects ofBMP-2 +/- PGE2 on RANKL and OPG
mRNA in marrow cultures.
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MATERIALS AND METHODS
Mice and Reagents. Male C57B1/5 mice (6 weeks old) were obtained from Charles
River (Wilmington, MA). PGE was purchased from Cayman Chemical Co (Ann
Arbor, MI). Indomethacin was purchased from Sigma (St. Louis, MO). BMP-2 was
purchased from R & D Systems (Minneapolis, MN). Vitamin D3 (1 c, 25(OH)2D3)
was purchased from Sigma.
Bone Marrow (BM) Cell Cultures. C57B1/6 mices were anesthetized with CO2 gas
and sacrificed by cervical dislocation. Femurs and tibias were dissected, the
epiphysises were cut off with scissors and the bone marrow was flushed out of the
diaphysis with 1 ml of alpha minimal essential medium ((x-MEM; Gibco BRL, Grand
Island, NY), 10% fetal calf serum (FCS; Gibco BRL), penicillin (100 U/ml) and
streptomycin (50 gg/ml) from each end and collected in a tube on ice. Cell viability
was >95% when counted using a hemocytometer and stained with either trypan blue
or acetic acid. BM cultures were plated in 48-well plates (1X106 cells/well), 12-well
plates (4X106 cells/well) or 6-well plates (8X106 cells/well). The medium was
changed every third day with the treatment. Treatment groups consisted of vehicle
control, vitamin D3 (10-SM), PGE2 (1 gM), BMP-2 (100 ng/ml) and the combination
ofPGE2+BMP-2.
Spleen Cell Cultures. C57B1/6 mice were anesthetized with CO2 gas, sacrificed by
cervical dislocation and the spleen removed. The spleen was minced between filter
paper in a petri dish with 10 ml cc-MEM (Gibco BRL), 10% FCS (Gibco BRL),
penicillin (100 U/ml) and streptomycin (50 gg/ml) until the cells were separated and
only a pale white mass remained. Cell viability was >95% when counted using a
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hemocytometer and stained with either trypan blue or acetic acid. Cells were plated in
48-well dishes at a low cell concentration (2.5X10 cells/well) or at a high
concentration (5X10s cells/well). The medium was changed every third day with the
treatment. Treatment groups consisted of vehicle control, vitamin D3 (10-8M), PGE2
(1 gM), BMP-2 (100 ng/ml) and the combination ofPGE2+BMP-2.
Tartrate-Resistant Acid Phosphatase (TRAP)-positive Multinulcleated Cells (MNC).
BM and spleen cell cultures on days 6, 7, 8, 9 and 10 were fixed with 5%
glutaraldehyde for 30 minutes at room temperature and washed with phosphate-
buffered saline. The cell cultures were stained for TRAP (a marker enzyme for
osteoclasts) using a leukocyte acid phosphatase A kit (Sigma). TRAP-positive cells
with 3 or more nuclei were counted under 100X magnification as osteoclast-like
multinucleated cells 1 ].
RNA Extraction. Total RNA was extracted from BM cell cultures with TRI-reagent
(UCHC Molecular Research Core) following company recommended protocol. Total
RNA (5 gg) was converted to cDNA by the High Capacity cDNA Archive Kit (ABI).
Aliquots of the reverse transcribed (RT) mixture were used for PCR.
Real-Time (rt) PCR. rtPCR was performed for different gene expression (GADPH,
RANKL, OPG, osteoclacin, alkaline phosphatase, COX-2) in separate wells of 12 well
dishes. GADPH served as endogenous control. Each sample was amplified using
Assays-on-Demand Gene Expression assay (ABI) which contained predesighned
unlabeled gene-specific PCR primers and TaqMan MGB FAM dye-labeled probe.
The PCR reaction mixture (including 2X TaqMan Universal PCR Master Mix, 20X
Assays-on-Demand Gene Expression Assay Mix, 50 ng of cDNA is run in Applied
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Biosystems ABI Prism 7500 Sequence Detection System instrument utilizing
universal thermal cycling parameters. Quantification was calculated by the AACt
method as described in the ABI manual.
Radioimmunoassay (RIA). Aliquots (500 gl) ofmedia from days 3,6,7 and 8 were
removed and frozen for later PGE: RIA. RIA was done on as described previously
[69]. In brief, unknown and standards contained equal amounts ofmedia. [3H]-
prostaglandin was used as a tracer and the assays run at antibody dilutions providing
20-40% binding. The lower detection limit of the assay for PGE2 was 5 pg/tube or
0.14 nM in a 100 gl sample, and the intra assay variation was 6%. The assays were
carried out at 4C and free prostaglandin removed with dextran-coated charcoal. The
values for unknowns are calculated from a standard curve using the logit-log, curve-
fitting computer program (Soft Pro Max).
Statistical Analysis. Results of groups are reported as mean+SEM and were compared
by ANOVA (SigmaStat, San Rafael, CA). The significance of differences was
determined by post hoc testing using the Bonferroni method. A probability (p-value)
of <0.05 was considered significant.
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RESULTS
Spleen Cell Cultures
To analyze the effect ofBMP-2 and PGE2 on OCs, spleen cell cultures were
plated at the low concentration (2.5xl 06 cells/well; n=3) and high concentration
(5x106 cells/well; n=3) in 48-well plates. In the low concentration, no difference in
osteoclastogenesis was observed between control and BMP-2 treatments on either
days 7 or 8 (Figures 4 and 5). Osteoclastogenesis in the PGE2 and PGE2+BMP-2
treatment groups were significantly decreased by more than halfwith no apparent
effect ofBMP-2 alone on the number of cells/well.
To determine the effects of plating density on the spleen cell cultures and
treatments, spleen cells were plated at a high concentration in 48-well plates and
cultured for 7 and 8 days showed no difference. On day 8, TRAP+ve MNC appeared
to be dying and the wells appeared almost confluent. Figure 6 shows the number of
TRAP+ve MNC/we11 on days 7 and 8. There was a small increase in OC number with
BMP-2 on day 7. PGE2 and PGE2+BMP-2 treatment groups were significantly
decreased on day 7. Only the PGE2+BMP-2 group had a significant decrease in cell
count on day 8 compared to control. It appears that the BMP-2 alone did not increase
osteoclastogenesis or in conjunction with PGE2 in spleen cell cultures, which are
primarily composed of osteoclastic precursors.
Bone Marrow (BM) Cultures
To study the effects ofBMP-2 and PGE2 on cell cultures containing both
osteoblastic and osteoclastic precursors, BM was plated at lx106 cells/well in 48-well
plates. The peak number ofTRAP+ve MNC was seen on day 8 for the Vitamin D3
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group with an equal peak for the PGE2+BMP-2 on day 9 (Figure 7). BMP-2 alone
treated cultures almost had no TRAP+ve MNC during the time course. While PGE2
did stimulate MNC production which peaked on day 8, it only reached a third of the
number for the Vitamin D3 and PGE2+BMP-2 groups. Figures 8 and 9 show plate
scans and photomicrographs of the treatment groups. Notice the differences in
staining and TRAP+ve MNC numbers.
To determine if the previous results were reproducible and if quantitative PCR
could be performed on the system, BM was plated at 8xl 06 cells/well in 6-well dishes.
Figure 10 shows plate scans with increased staining on day 8 for the PGE2 and
PGE2+BMP-2 treatments, with almost all the staining disappearing by day 9. Table 1
shows a peak in TRAP+ve MNC on day 7 for the PGE2+BMP-2 group, more than
double that for the PGE2 alone treatment. Comparing this to the previous plating at
lxl 06 cells/well in 48-well plates (Figure 7), there is a difference of one day when the
peak number of TRAP+ve MNC are formed.
Quantitative PCR for RANKL and OPG and showed the highest ratio of
RANKL:OPG on day 7 with the PGE2+BMP-2 group, while only a minor increase
was observed for PGE2 (Figure 11). Osteocalcin showed a drastic rise in levels for the
BMP-2 treatment group on day 9 suggesting that BMP-2 stimulated osteoblatic
differentiation.
BM was then plated at 4x106 cells/well in 12-well plates (n=3) to increase the
sample number and to still be able to obtain enough RNA for quantitative PCR
analysis. Figures 12 and 13 show plate scans and photomicrographs. TRAP+ve MNC
appear in clusters with dense purple stained cells surrounding the cluster. Some wells
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in the control and BMP-2 group do have stain located in the center, however no MNC
were present. Rather, these cells appeared in a similar arrangement to those
surrounding the cluster ofTRAP+ve MNC in the other 2 treatment groups. Figure 14
shows a significant stimulation of TPAP+ve MNC on day 9 for the combination
treatment group compared to the other groups. On day 8, there were comparable
levels ofMNC in the PGE2 and combination groups compared to control and BMP-2
treatment.
Similar to the findings in the 6-well dishes, Figure 15 shows a 5-fold increase
in RANKL in PGE2+BMP-2 treatment compared to the control and BMP-2 groups on
days 7 and 8 in 12-well dishes. RANKL mRNA was also elevated in the PGE2
treatment group, but not to the relative amount in the combination treatment. The
combination group showed significantly lower levels ofOPG mRNA on days 8 and 9
(Figure 16). The relative ratio ofRANKL:OPG is thought to have the most important
effect on osteoclastogenesis and Figure 17 shows the greatest ratio on days 7 and 8 for
the combination treatment, two days before the peak in TRAP+ve MNC number,
potentially indicating a mechanism for osteoclastogenesis.
Alkaline phosphatase, an early marker for OB differentiation showed
asignificantly higher levels ofmRNA in the combination group (days 7 and 8), while
the PGE2 treament was significantly lower (day 8), implying less OB differentiation
with the addition ofPGE2 than in the combination group (Figure 18). BMP-2 alone
did not stimulate alkaline phosphatase levels.
Indomethacin, an NSAID, was added to all groups to determine the effects of
endogenous PG production on osteoclastogenesis. Figure 19 shows that the addition
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of indomethacin had no effect on RANKL, OPG or COX-2 production on Day 8
except in BMP-2 group. A significant increase in OPG production with the addition
of indomethacin was observed.
PGE2 levels in the media were quantified via RIA (Figure 20). The addition of
indomethacin significantly decreased the amount ofPGE2 in the media on day 6,
however day 7, there was increase, which subsided by day 8. It is important to note
that the media was changed on days 3 and 6, which could explain the rise on day 7 as
a result of the media change stimulating PGE2 production. The level ofproduction
was blocked by day 8 in the indomethacin groups.
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DISCUSSION
Bone morphogenetic protein (BMP)-2 is a potent stimulator ofnew bone
formation with a potential role in dental regenerative therapies and improving dental
implants. There are studies showing that effects ofBMP-2 on bone formation may be
mediated in part by prostaglandins [1] or enhanced by exogenous addition ofPGs
[21 ]. PGE is a potent stimulator ofOC formation and BMP-2 can induce and also
stimulate OC COXo2 expression and PGE production. The goal of this study was to
examine how the effects ofBMP-2 on osteoclastogenesis are enhanced by PGE2 (or
how the effects ofPGE2 on osteoclastogenesis are enhanced by BMP-2).
The first question was whether or not the enhancement reflected an effect on
the osteoclast precursor. To study this, we used murine spleen cells supplied with
those factors, RANKL and M-CSF, which are usually supplied by the osteoblastic
lineage. We tried several different plating densities and time points. There was a
slight increase in osteoclast numbers in one treatment group with BMP-2 (100 ng/ml)
alone but in no case did the combination ofBMP-2 + PGE2 increase osteoclast number
compared to PGE2 alone or to BMP-2 alone. Hence, although there may be some
small effect ofBMP-2 on osteoclast precursors, this effect does not appear to account
for the markedly increased effect previously seen with the combination ofBMP-2 +
PGE2.
The next question was whether or not the enhancement reflected an effect on
the osteoblastic supporting cells to increase RANKL or OPG expression. For this
study we used MSC from murine long bones. Before we could answer this question,
we needed to establish a model system in which we could both count TRAP+ MNCs
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and extract sufficient RNA to do real time PCR from an n=3 wells. We tried several
size wells and finally settled on 12-well dishes. We counted OCs in 3 individual wells
and pooled 2 wells per treatment group x 3 for RNA. Along the way we observed that
plating in different size wells, despite trying to plate at the same density, resulted in
different time courses for the peak values of osteoclastogenesis. Hence, we think it is
important to obtain mRNA for gene expression from the same type ofplates in which
OCs are counted or the correlations could be misleading.
The role ofBMP-2 on PGE2 production and action in bone resorption is
unknown and how these proteins affect the RANK/RANKL/OPG balance has not been
deciphered. The purpose of this study was to determine the role ofBMP-2, COX-2
and PGEz on osteoclastogenesis in both bone marrow and spleen cell cultures. There
has been increased interest and possible therapeutic potential for BMP intervention
associated with bone development, differentiation, maturation and homeostasis, it
therefore seems apparent that the effects ofBMPs on osteoclasts and
osteoclastogenesis should be investigated. In the dental field, potential therapeutics
involve bone fracture repair in oral and maxillofacial trauma [3], bone regeneration
and bone grafts [20] and osseointegration of dental implants. The major problem
however is that small amounts ofBMPs are extremely costly and usually milligrams
of the protein are required to elicit new bone formation so cheaper methods and/or
adjuncts to manipulate the mechanism by which bone remodeling occurs would be
beneficial.
In the first study to examine BMP-2 effects on osteoclast-like cell formation
and bone resorbing activity, Kanatani et al. [70] found that BMP-2 alone (1-100
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ng/ml) stimulated OC bone resorption activity measured on dentine slice in preexisting
BDF-1 and ICR mouse cultures, but not in rabbit cultures. BMP-2 was also found to
enchace the effect of 1,25-dihydroxyvitamin D3. In our study, BMP-2 alone had no
effect on TRAP+ve number. This may be due to the use of different types of cell
cultures rather than differences in BMP-2 concentrations. They used preexisting OCs,
whereas we used spleen cells as precursors to OCs. In our experiment, there was no
evidence that BMP-2 alone induced osteoclastogenesis in spleen cell culture (i.e
precursors to multinucleated osteoclast-like cells). In addition, their cultures
contained GM-CSF in addition to BMP-2, whereas we used RANKL and m-CSF.
Kanatani et al. concluded BMP-2 stimulated bone resorption through both direct
stimulation of OC formation and activation of mature osteoclast. Unfortunately our
results do not support this finding.
Chikazu et al. [1] found that in cultured marrow cells flushed from long bones,
BMP-2 induced OC formation in the COX-2 +/+ but not the COX-2 knockout (-/-)
mice as counted by TRAP +ve staining. A synergistic increase in OC number was
found with the addition ofboth BMP-2+PGE2 compared to either alone. Our study
also found a synergistic increase in OCs. Furthermore, this synergism was also seen
in the COX-2 -/- cultures with the addition ofboth proteins together. COX-2 mRNA
and PG production was induced by BMP-2 in cultured calvarial OBs as well.
Furthermore, cultured OBs from COX-2 -/- mice versus wild-type (+/+) showed
reduced BMP-2 stimulation ofALP and osteocalcin mRNA expression. Our study
showed no significant change in osteocalcin production. This difference may be due
to osteocalcin being a late marker for more mature OBs and in the Chikazu study,
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cultures were taken to day 14, whereas in our study, the time course was from days 6-
10. On the other hand, ALP production had increased over time in the cultures
showing much more ALP mRNA induction in the combination group compared to
control and BMP-2 alone. The addition ofPGE seemed to inhibit ALP. ALP is an
early OB marker and can this can be either an increase in ALP mRNA production in
OBs or hyperplasia of early OBs. This difference in ALP stimulation may also be
attributed to different points in the time course of OB maturation between the studies.
In another study by Kaneko et al. [71 ], using purified rabbit mature osteoclast
cells, BMP-2 caused a dose and time dependent increase in pit formation on dentine
slices. This was abolished with the addition of follistatin, a BMP binding protein.
Type IA and II BMP receptors were also detectable. As stated above, we did not find
obvious effect ofBMP-2 in spleen cell cultures (i.e precursor cultures) which may
account for the difference seen in the mature OC cultures.
Koide et al. [68]. Found BMP-2 enhances osteoclastogenesis via IL-la
through upregulation of osteoclast differentiation factor (ODF or RANKL) and COX-
2. Bone marrow cells co-cultured with calvarial cells from ddy mice were used and no
TRAP +ve cells were observed with the addition of only varying concentrations of
BMP-2. Our study showed the same results using a standard concentration. In
contrast to Chikazu [1], a small number of OCs were observed in the COX-2 +/+
mice, but none in the knockouts. With the addition of IL-1 (x (a member of the TNF-c
family as is RANKL), BMP-2 stimulated TRAP+ve cells in a dose-dependent manner
[68]. A western blot showed a synergistic induction of COX-2 in the combination
group as well. Our study using qPCR showed an increase in COX-2 mRNA in the
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PGE2 group and a synergistic increase in the combination group (data not shown). A
northern analysis showed the same with ODF/RANKL. Similar results were seen in
our experiment with the addition of the combination group (BMP-2+PGE2). RANKL
mRNA increased, and OPG mRNA decrease with ratio ofRANKL:OPG increasing
(Figure 17). The balance between the two plays a critical role in the differentiation of
OBs and OCs as well as in bone remodeling. The addition of indomethacin (non-
specific NSAID) and NS-398 (selective COX-2 inhibitor) blocked osteoclastogenesis
in a dose-dependent manner [68]. It seems apparent that BMP-2 in conjunction with
others molecules may enahance osteoclastogenesis and the mechanism may be
mediated through COX-2 and PG production.
Ono et al. [20] has found increased bone production around pellets with BMP-
2+PGE2 formation in rabbits and has suggested that an enormous reduction in the
amount ofrhBMP can be administed when PGs are used in conjunction. This may be
the case, however, in our results suggest that an increase in osteoclastogenesis occurs.
If there is a possible way to inhibit osteoclastogenesis and force the balance in bone
remodeling toward bone formation rather than bone resorption, the use ofPGs to
enhance BMP-2 stimulated bone formation may even be further advanced.
The relative ratio ofRANKL:OPG is thought to have the most important effect
on osteoclastogenesis. Our results show the greatest ratio two days before the peak in
osteoclastogenesis occurs which may signify a temporal relationship between the
synergistic effects ofPGE2+BMP-2, compared to PGE2 alone. Despite OPG mRNA
at its lowest level on day 9 for the combination group, the relative amounts ofprotein
RANKL and OPG may dictate the formation of OCs on those days. Using alkaline
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alkaline phosphatase as a marker of early OBs, we showed that it increases during the
time course. This may represent either more early OB formation or more alkaline
phosphatase formation per OB. The increase in OBs may account for the increase in
OCs through an overall anabolic effect ofBMP-2+PGE2.
Another possible mechanism may be that BMP-2 may change the proportion of
early OBs in the culture by decreasing OB apoptosis, thus having more differentiating
OBs in the culture. BMP-2 may induce COX-2 and this may result in more PGE2
production. Therefore, the addition ofboth BMP-2+PGE2 may in reality be due an
increase in PGE2. However, the addition of indomethacin to the treatment groups had
no effect on the production ofRANKL, OPG or COX-2 mRNA except in the BMP-2
group which increases OPG production. BMP-2 may have an effect on OPG
production, thus changing the RANKL:OPG ratio. This may in tum be counteracted
by the addition of PGE2. Further investigation is needed.
In conclusion, the addition ofBMP-2 alone did not increase
osteoclastogenesis, but did increase OC formation in the presence of exogenous PGE2.
The effect of the BMP-2+PGE2 combination correlated with an increase in RANKL
and a decrease in OPG expression. It is possible that the increased activation of
resorption in vivo by PGE2 will permit BMP-2 to have a greater anabolic effect by
increasing the number ofremodeling sites at which BMP-2 can act. However, this
relationship appears to be dependent on many factors that have yet to be deciphered.
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Figure 1. The genes responsible for bone induction that have been cloned. [2]
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